Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DR26FMDX3
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $24,403
Award facts
- Contract value 100% obligated
- $24,403.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $24.4K delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Entyvio 300 mg vials. Issued on November 17, 2025, with an ultimate completion date of November 18, 2025, this firm fixed-price delivery order carries no set-aside designation, reflecting the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which was established on November 13, 2025, with a $499.9B ceiling value extending through December 31, 2036.
The PPV-G GEN V represents a $30.3B acquisition strategy designed to support Department of Defense healthcare operations globally through a network of regional prime vendor contractors. This delivery order exemplifies DMS Pharmaceutical Group's role as a critical supplier within the federal pharmaceutical supply chain, delivering specialized biologics and immunosuppressant medications to military healthcare facilities. The vendor's established performance across numerous delivery orders and its comprehensive product portfolio spanning branded and generic pharmaceuticals, vaccines, and specialty medical consumables demonstrate its capability to meet the diverse pharmaceutical requirements of the federal military medical system.
Quick answers
Who was awarded contract SPE2DR26FMDX3?
SPE2DR26FMDX3 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 17, 2025.
How much is contract SPE2DR26FMDX3 worth?
The government has obligated $24,403 on SPE2DR26FMDX3.
Is contract SPE2DR26FMDX3 an order under another contract?
Yes. SPE2DR26FMDX3 is a delivery order under SPE2DR25D9114, an indefinite delivery contract.
Was contract SPE2DR26FMDX3 competed?
The extent of competition for SPE2DR26FMDX3 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award